Zuzanna Maria Filipiak

Zuzanna Maria Filipiak

Auto-generated profile, based on publicly available information

Zuzanna Maria Filipiak

University Clinical Hospital in Opole, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2026 in Health Problems of Civilization
Verified
Journal Article
Open access
PDF file
MMMarcin Masłowski
Marcin Masłowski
PDPiotr Dudziak
Piotr Dudziak
TWTomasz Woźniak
Tomasz Woźniak
ZFZuzanna Filipiak
Zuzanna Filipiak
ŁWŁukasz Wabiszczewicz
Łukasz Wabiszczewicz
ASAlicja Sokołowska
Alicja Sokołowska
Vitamin D plays a crucial role in the regulation of calcium-phosphate metabolism and the proper functioning of multiple body systems. The widespread prevalence of vitamin D deficiency has led to a significant increase in supplementation in the general population over recent years. However, this trend has been accompanied by a growing number of cases of hypervitaminosis D, primarily resulting from uncontrolled intake of high-dose vitamin D preparations. Excess vitamin D leads to disturbances in calcium homeostasis, most notably hypercalcemia, which may manifest itself in nonspecific systemic symptoms and result in serious organ complications such as nephrocalcinosis and renal failure. A major contributing factor is the widespread availability of vitamin D-containing preparations, combined with insufficient patient awareness of the potential consequences of excessive intake. Therefore, the aim of this work is to present the current state of knowledge regarding hypervitaminosis D and its significance from a public health perspective. An analysis of literature indicates that physicians play a key role in the rational management of vitamin D supplementation, identification of risk factors, and patient education. Adherence to current supplementation guidelines and regular monitoring of therapy can significantly reduce the risk of developing hypervitaminosis D.

30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAlicja Sokołowska
Alicja Sokołowska
MGMaria Golińska
Maria Golińska
NWNatalia Wasilewska
Natalia Wasilewska
MMMarcin Masłowski
Marcin Masłowski
PDPiotr Dudziak
Piotr Dudziak
ZFZuzanna Filipiak
Zuzanna Filipiak
Obesity has become a major global public health concern, with increasing prevalence among women of reproductive age. The aim of this study was to analyze the relationship between obesity and female fertility based on scientific evidence from studies indexed in the PubMed database. A literature review was conducted including peer-reviewed articles evaluating the impact of body mass index (BMI) on reproductive parameters such as menstrual regularity, ovulation, ovarian reserve, time to pregnancy, and outcomes of assisted reproductive technologies (ART). The findings indicate that obesity negatively affects fertility through hormonal imbalance, insulin resistance, chronic inflammation, and disruption of the hypothalamic–pituitary–ovarian axis. Obese women are more likely to experience ovulatory dysfunction, prolonged time to conception, and reduced effectiveness of ART procedures. Additionally, obesity is associated with poorer oocyte quality, lower implantation rates, and increased risk of miscarriage. Evidence suggests that moderate weight loss can significantly improve reproductive outcomes. In conclusion, obesity represents an important modifiable risk factor for female infertility, and appropriate lifestyle interventions may enhance fertility potential.

26 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
NKNatalia Kita
Natalia Kita
ZFZuzanna Maria Filipiak
Zuzanna Maria Filipiak
ANAnna Nowak
Anna Nowak
ŁWŁukasz Wabiszczewicz
Łukasz Wabiszczewicz
PDPiotr Marcin Dudziak
Piotr Marcin Dudziak
TWTomasz Woźniak
Tomasz Woźniak
Mental health disorders, including depression and anxiety, represent a major global health challenge and significantly affect quality of life and daily functioning (World Health Organization, 2023; Harvey et al., 2018). Increasing attention has been directed toward lifestyle factors, particularly physical activity, as potential strategies for improving psychological well-being (Firth et al., 2020; Ashdown-Franks et al., 2020). The aim of this narrative review is to summarize current evidence regarding the relationship between physical activity and mental health, with particular focus on depression and anxiety, and to highlight implications for public health and digital interventions. A narrative review methodology was applied based on literature retrieved from PubMed and Google Scholar, focusing on studies published between 2010 and 2025. The available evidence consistently demonstrates that regular physical activity is associated with reduced symptoms of depression and anxiety and improved overall psychological well-being (Singh et al., 2023; Schuch et al., 2018; Noetel et al., 2024). These effects are mediated through biological and psychological mechanisms (Kandola et al., 2019; Dishman et al., 2006). Furthermore, digital technologies such as wearable devices and mobile health applications are increasingly used to promote physical activity and support mental health outcomes (Patel et al., 2015; Wang et al., 2022). In conclusion, physical activity represents an effective and accessible complementary strategy in the prevention and management of mental health disorders.

6 November 2026 in Medical Science Pulse
Verified
Journal Article
Closed access
ŁWŁukasz Wabiszczewicz
Łukasz Wabiszczewicz
ZFZuzanna Maria Filipiak
Zuzanna Maria Filipiak
MGMaria Golińska
Maria Golińska
ANAnna Nowak
Anna Nowak
TWTomasz Woźniak
Tomasz Woźniak
ASAlicja Sokołowska
Alicja Sokołowska
Background: Hypertension remains one of the leading causes of cardiovascular morbidity and mortality worldwide. Despite the availability of effective antihypertensive medications, blood pressure control remains suboptimal in many patients, and adverse effects associated with pharmacotherapy have stimulated interest in complementary therapeutic strategies. Functional mushrooms are a rich source of bioactive compounds capable of modulating multiple molecular pathways involved in blood pressure regulation and therefore represent promising candidates for cardiovascular prevention.Aim of the study: This narrative review critically summarizes the current evidence regarding the antihypertensive potential of selected functional mushrooms by integrating mechanistic, in vitro, preclinical, and clinical findings. Particular emphasis is placed on the biological mechanisms underlying their activity, the quality of the available evidence, methodological limitations, and factors influencing the clinical translation of experimental findings.Material and methods: A literature search was conducted in January 2026 using PubMed and Google Scholar. Eligible publications included mechanistic studies, in vitro experiments, animal studies, human clinical trials, and relevant review articles investigating the effects of selected functional mushrooms on blood pressure regulation and related cardiovascular pathways.Results: Research identifies angiotensin-converting enzyme inhibition as the primary antihypertensive mechanism, with many mushroom-derived peptides (e.g., WALKGYK from T. matsutake and APPLRP from G. frondosa) acting as non-competitive or mixed-type inhibitors. Other identified mechanisms include enhancing nitric oxide bioavailability through the inhibition of arginase and acetylcholinesterase, and stimulating natriuresis via the Corin–ANP pathway. Animal studies consistently demonstrate reductions in systolic blood pressure and improvements in vascular remodeling. Human clinical evidence remains limited and inconsistent, and methodological heterogeneity together with insufficient standardization of mushroom preparations emerged as the principal barriers to clinical translation.Conclusions: Functional mushrooms represent a promising source of bioactive compounds with potential complementary applications in hypertension management. However, current evidence is supported predominantly by mechanistic and preclinical studies, whereas robust clinical confirmation remains insufficient. Future well-designed randomized controlled trials using chemically characterized and standardized mushroom preparations are essential to establish their efficacy, safety, and potential role in evidence-based hypertension management.

15 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ANAnna Nowak
Anna Nowak
TWTomasz Woźniak
Tomasz Woźniak
ZFZuzanna Filipiak
Zuzanna Filipiak
MGMaria Golińska
Maria Golińska
PDPiotr Dudziak
Piotr Dudziak
TMTomasz Mróz
Tomasz Mróz
Introduction: Pain is one of the most common complaints associated with physical activity, both in professional and recreational sports. As a physiological and subjective phenomenon, pain serves a protective function, warning of potential injury or overuse. However, if left untreated, it may lead to chronic pain conditions, impaired motor function, or even permanent exclusion of the athlete from activity. Therefore, effective and safe pain management is essential to maintain training continuity, prevent complications, and support athletes’ optimal psychophysical performance. Standard therapeutic approaches in athletes typically involve the use of nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and—in the case of more severe pain—opioid medications. However, increasing attention has been paid to coanalgesics, a group of drugs that are not classified as traditional analgesics but exhibit supportive or potentiating effects on pain relief. Coanalgesics—including antidepressants, anticonvulsants, glucocorticoids, local anesthetics, and even certain dietary supplements—are especially useful in treating neuropathic, chronic, or multifactorial pain. In the context of sports, these agents may play a crucial role in reducing the required doses of standard analgesics, minimizing side effects, and facilitating return to full physical functionality. Given the unique characteristics of the sports environment—including time pressure, high physical demands, anti-doping regulations (e.g., WADA), and ethical considerations—appropriate analgesic selection must not only be effective but also safe, rational, and compliant with governing rules. When used appropriately, coanalgesics may serve as alternatives or adjuncts to classical pain management strategies. Aim: The aim of this paper is to analyze the role of coanalgesics in pain therapy among athletes, with reference to data from recent clinical trials, systematic reviews, and scientific society guidelines. Particular attention is given to the efficacy, safety, and limitations of selected substances in various pain types—acute, chronic, somatic, and neuropathic—with respect to sports disciplines and return-to-play protocols. Material and Methods: This narrative review was conducted to synthesize current evidence regarding the use of coanalgesics in the management of pain among athletes, with a particular focus on neuropathic, postoperative, and post-traumatic pain. A structured literature search was performed in PubMed, Scopus, and Web of Science. Conclusions: Co-analgesics offer a promising tool in pain management among athletes. Paracetamol and topical analgesics may reduce pain-related limitations without the long-term risks associated with systemic agents. However, the overuse of NSAIDs and the application of opioids carry serious health and ethical concerns. Further high-quality research is needed to establish optimal treatment protocols and to promote education within sports communities.

13 August 2026 in Pharmacotherapy in Psychiatry and Neurology
Verified
Journal Article
Open access
TWTomasz Woźniak
Tomasz Woźniak
ZFZuzanna Maria Filipiak
Zuzanna Maria Filipiak
ASAlicja Sokołowska
Alicja Sokołowska
MMMarcin Masłowski
Marcin Masłowski
ŁWŁukasz Wabiszczewicz
Łukasz Wabiszczewicz
PDPiotr Marcin Dudziak
Piotr Marcin Dudziak
Pharmacotherapy in Psychiatry and Neurology